Health Care [ 4/12 ] | Biotechnology [ 14/75 ]
NASDAQ | Common Stock
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor.
The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.
Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 26 | 0.13 Increased by +244.44% | 0.09 Increased by +46.73% |
| Nov 5, 25 | 0.06 Increased by +118.18% | -0.10 Increased by +159.76% |
| Aug 6, 25 | -0.13 Increased by +69.05% | -0.17 Increased by +23.53% |
| May 12, 25 | -0.20 Increased by +37.50% | -0.73 Increased by +72.60% |
| Feb 25, 25 | -0.09 Increased by +87.50% | -0.26 Increased by +65.95% |
| Nov 6, 24 | -0.33 Increased by +54.79% | -0.42 Increased by +21.43% |
| Aug 14, 24 | -0.42 Increased by +63.79% | -0.52 Increased by +19.23% |
| May 14, 24 | -0.32 Increased by +75.57% | -0.73 Increased by +56.16% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 129.50 M Increased by +81.48% | 17.39 M Increased by +261.24% | Increased by +13.43% Increased by +188.85% |
| Sep 30, 25 | 99.22 M Increased by +121.69% | 7.41 M Increased by +117.84% | Increased by +7.47% Increased by +108.05% |
| Jun 30, 25 | 81.50 M Increased by +164.13% | -15.89 M Increased by +69.64% | Decreased by -19.49% Increased by +88.51% |
| Mar 31, 25 | 65.85 M Increased by +32.84% | -25.06 M Increased by +29.17% | Decreased by -38.06% Increased by +46.68% |
| Dec 31, 24 | 71.36 M Increased by +427.58% | -10.79 M Increased by +83.72% | Decreased by -15.12% Increased by +96.92% |
| Sep 30, 24 | 44.76 M Increased by +17.44% | -41.54 M Increased by +7.21% | Decreased by -92.81% Increased by +20.99% |
| Jun 30, 24 | 30.86 M Increased by +494.57% | -52.33 M Increased by +26.28% | Decreased by -169.59% Increased by +87.60% |
| Mar 31, 24 | 49.57 M Increased by +1.68 K% | -35.38 M Increased by +55.63% | Decreased by -71.38% Increased by +97.51% |